Bioxcel therapeutics reports q4 and full year 2019 financial results

Bioxcel therapeutics reports fourth quarter and full year 2019 financial results and provides business update.bioxcel therapeutics - key bxcl501 data readouts expected in mid 2020 including results from serenity program & phase 1b/2 tranquility trial in geriatric dementia.bioxcel therapeutics - stock offering proceeds of $60 million & current reserves provide co cash runway to fund key clinical, regulatory & operational milestones into 2021.bioxcel therapeutics inc - reported net loss of $8.3 million for q4 of 2019.
BTAI Ratings Summary
BTAI Quant Ranking